ANAB
Closed
Anaptysbio Inc
22.65
+0.45 (+2.03%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 22.2
Day's Range: 21.87 - 23.09
Send
sign up or login to leave a comment!
When Written:
21.76
AnaptysBio Inc. is a clinical-stage biotechnology company that specializes in the development of therapeutic antibodies for the treatment of inflammatory and autoimmune diseases. The company's proprietary platform, called somatic hypermutation, allows for the rapid discovery and optimization of fully human antibodies with high specificity and affinity for their targets.
AnaptysBio's lead product candidate, etokimab, is a potential treatment for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The company is also developing other product candidates targeting various inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease, and multiple sclerosis.
Founded in 2005, AnaptysBio is headquartered in San Diego, California, and has a research facility in Cambridge, Massachusetts. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol ANAB.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
AnaptysBio's lead product candidate, etokimab, is a potential treatment for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The company is also developing other product candidates targeting various inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease, and multiple sclerosis.
Founded in 2005, AnaptysBio is headquartered in San Diego, California, and has a research facility in Cambridge, Massachusetts. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol ANAB.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








